EECP is one of the most evidence-backed therapies in cardiology that many physicians still don’t fully understand, and even fewer feel confident explaining to patients.
‍

In this conversation, I sit down with Michael Gratch, Founder and President of Flow Therapy, to talk about what it actually takes to build a healthcare company centered on EECP, or enhanced external counterpulsation, inside a complex medical system. Michael’s journey began with one patient, his grandfather, who had undergone multiple bypass surgeries, stents, and had no remaining revascularization options. Quality of life mattered, and there were few answers being offered.

EECP is not alternative medicine. It is a noninvasive cardiovascular therapy supported by decades of research, offered at major academic centers, and covered by Medicare. And yet, access remains limited, adoption uneven, and understanding incomplete. Michael shares how that gap between evidence and availability became the catalyst for building what is now Flow Therapy.

If you are a doctor who has ever struggled to explain EECP to a patient, questioned why effective therapies remain underutilized, or felt the strain of practicing inside a system resistant to change, this conversation will resonate.